Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Genitourinary Cancer|February 21, 2021
Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV StudyFernando C Maluf, Fabrício A M de Oliveira, Pedro E R Liedke, et al.
Oncotarget|November 16, 2017
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trialsRaphael B Moreira, Marcio Debiasi, Edoardo Francini, et al.
Cancer|August 12, 2009
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinomaDavid J Gallagher, Matthew I Milowsky, Alexia Iasonos, et al.
Critical Reviews in Oncology/Hematology|July 16, 2019
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trialsViviane C Ruiz-Schutz, Larissa M Gomes, Rodrigo C Mariano, et al.
The Oncologist|September 2, 2024
Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational studyFernando Sabino Marques Monteiro, Antonio Machado Alencar Junior, Karine Martins da Trindade, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)Fernando C Maluf, Fabio A Schutz, Eduardo H Cronemberger, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.
Pageof 2